Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity

Cancer Cell International

Volumn 9, Issue , 2009, Pages

  Freeburg, Elizabeth M ^a   Goyeneche, Alicia A ^a   Seidel, Erin E ^a   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; GENOMIC DNA; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMETRY; DIPLOIDY; DNA CONTENT; DNA FRAGMENTATION; DOWNSTREAM PROCESSING; DRUG CYTOTOXICITY; DRUG RESEARCH; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PROTEIN CLEAVAGE;

EID: 63549092395     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-9-4     Document Type: Article

References (65)

1. DiSaia PJ Bloss JD Treatment of ovarian cancer: New strategies Gynecol Oncol 2003, 90(2 Pt 2):S24-32 12928003
2. Aletti GD Gallenberg MM Cliby WA Jatoi A Hartmann LC Current management strategies for ovarian cancer Mayo Clin Proc 2007, 82(6):751-770 17550756
3. Bhoola S Hoskins WJ Diagnosis and management of epithelial ovarian cancer Obstet Gynecol 2006, 107(6):1399-1410 16738170
4. Herzog TJ The current treatment of recurrent ovarian cancer Curr Oncol Rep 2006, 8(6):448-454 17040623
5. Fraser M Leung B Jahani-Asl A Yan X Thompson WE Tsang BK Chemoresistance in human ovarian cancer: The role of apoptotic regulators Reprod Biol Endocrinol 2003, 1(1):66 270001 14609433
6. Hamilton TC Johnson SW Recent insights into drug resistance in ovarian cancer Ovarian Cancer: Methods and Protocols NJ: Humana Press Barlett JMS 2000:89-106
7. Vasey PA Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies Br J Cancer 2003, 89(Suppl 3):S23-28 14661043
8. Kelland L The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 2007, 7(8):573-584 17625587
9. Rabik CA Dolan ME Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat Rev 2007, 33(1):9-23 1855222 17084534
10. Goyeneche AA Caron RW Telleria CM Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo Clin Cancer Res 2007, 13(11):3370-3379 2505183 17545545
11. Katano K Kondo A Safaei R Holzer A Samimi G Mishima M Kuo YM Rochdi M Howell SB Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper Cancer Res 2002, 62(22):6559-6565 12438251
12. Ormerod MG O'Neill C Robertson D Kelland LR Harrap KR cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines Cancer Chemother Pharmacol 1996, 37(5):463-471 8599870
13. Arimoto-Ishida E Ohmichi M Mabuchi S Takahashi T Ohshima C Hayakawa J Kimura A Takahashi K Nishio Y Sakata M et al. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin Endocrinology 2004, 145(4):2014-2022 14701673
14. Hayakawa J Ohmichi M Kurachi H Ikegami H Kimura A Matsuoka T Jikihara H Mercola D Murata Y Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line J Biol Chem 1999, 274(44):31648-31654 10531373
15. Giono LE Manfredi JJ The p53 tumor suppressor participates in multiple cell cycle checkpoints J Cell Physiol 2006, 209(1):13-20 16741928
16. Farid NR P53 and other cell cycle regulators Cancer Treat Res 2004, 122:149-164 16209043
17. Kuribayashi K El-Deiry WS Regulation of programmed cell death by the p53 pathway Adv Exp Med Biol 2008, 615:201-221 18441595
18. Garner E Raj K Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death Cell Cycle 2008, 7(3):277-282 18235223
19. Stiewe T The p53 family in differentiation and tumorigenesis Nat Rev Cancer 2007, 7(3):165-168 17332760
20. Helton ES Chen X p53 modulation of the DNA damage response J Cell Biochem 2007, 100(4):883-896 17031865
21. Ford JM Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53 Mutat Res 2005, 577(1-2):195-202 15927209
22. Sengupta S Harris CC p53: Traffic cop at the crossroads of DNA repair and recombination Nat Rev Mol Cell Biol 2005, 6(1):44-55 15688066
23. Reles A Wen WH Schmider A Gee C Runnebaum IB Kilian U Jones LA El-Naggar A Minguillon C Schonborn I et al.: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res 2001, 7(10):2984-2997 11595686
24. Astanehe A Arenillas D Wasserman WW Leung PC Dunn SE Davies BR Mills GB Auersperg N Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer J Cell Sci 2008, 121(Pt 5):664-674 18270270
25. Yang X Fraser M Moll UM Basak A Tsang BK Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitochondrial death pathway Cancer Res 2006, 66(6):3126-3136 16540663
26. Fraser M Bai T Tsang BK Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function Int J Cancer 2008, 122(3):534-546 17918180
27. Mujoo K Zhang L Klostergaard J Donato NJ Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement Int J Gynecol Cancer 2000, 10(2):105-114 11240661
28. Huang X Halicka HD Traganos F Tanaka T Kurose A Darzynkiewicz Z Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis Cell Prolif 2005, 38(4):223-243 1360473 16098182
29. Scovassi AI Poirier GG Poly(ADP-ribosylation) and apoptosis Mol Cell Biochem 1999, 199(1-2):125-137 10544961
30. Fraser M Leung BM Yan X Dan HC Cheng JQ Tsang BK p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells Cancer Res 2003, 63(21):7081-7088 14612499
31. Yaginuma Y Westphal H Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines Cancer Res 1992, 52(15):4196-4199 1638534
32. Reid T Jin X Song H Tang HJ Reynolds RK Lin J Modulation of Janus kinase 2 by p53 in ovarian cancer cells Biochem Biophys Res Commun 2004, 321(2):441-447 15358195
33. O'Connor PM Jackman J Bae I Myers TG Fan S Mutoh M Scudiero DA Monks A Sausville EA Weinstein JN et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Res 1997, 57(19):4285-4300 9331090
34. Ikediobi ON Davies H Bignell G Edkins S Stevens C O'Meara S Santarius T Avis T Barthorpe S Brackenbury L et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol Cancer Ther 2006, 5(11):2606-2612 17088437
35. Andrews PA Murphy MP Howell SB Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion Cancer Res 1985, 45(12 Pt 1):6250-6253 4063975
36. Andrews PA Murphy MP Howell SB Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells Cancer Chemother Pharmacol 1987, 19(2):149-154 3568272
37. Hamilton TC Winker MA Louie KG Batist G Behrens BC Tsuruo T Grotzinger KR McKoy WM Young RC Ozols RF Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion Biochem Pharmacol 1985, 34(14):2583-2586 4040369
38. Sasaki H Sheng Y Kotsuji F Tsang BK Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells Cancer Res 2000, 60(20):5659-5666 11059757
39. Siddik ZH Mims B Lozano G Thai G Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line Cancer Res 1998, 58(4):698-703 9485023
40. Lu X Errington J Curtin NJ Lunec J Newell DR The impact of p53 status on cellular sensitivity to antifolate drugs Clin Cancer Res 2001, 7(7):2114-2123 11448931
41. Righetti SC Perego P Corna E Pierotti MA Zunino F Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection Cell Growth Differ 1999, 10(7):473-478 10437915
42. Song K Li Z Seth P Cowan KH Sinha BK Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas Oncol Res 1997, 9(11-12):603-609 9563008
43. Freeburg EM Goyeneche AA Telleria CM Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment Int J Oncol 2009, 34(3):743-755 19212679
44. Rose FV Barnea ER Response of human ovarian carcinoma cell lines to antiprogestin mifepristone Oncogene 1996, 12(5):999-1003 8649817
45. Schoenlein PV Hou M Samaddar JS Gaddy VT Thangaraju M Lewis J Johnson M Ganapathy V Kallab A Barrett JT Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer Int J Oncol 2007, 31(3):643-655 17671693
46. Gaddy VT Barrett JT Delk JN Kallab AM Porter AG Schoenlein PV Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells Clin Cancer Res 2004, 10(15):5215-5225 15297425
47. Liang Y Hou M Kallab AM Barrett JT El Etreby F Schoenlein PV Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: A role for TGFbeta1 Int J Oncol 2003, 23(2):369-380 12851686
48. Horwitz KB The antiprogestin RU38 486: Receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells Endocrinology 1985, 116(6):2236-2245 4039656
49. Mao J Regelson W Kalimi M Molecular mechanism of RU 486 action: A review Mol Cell Biochem 1992, 109(1):1-8 1614417
50. El-Deiry WS The role of p53 in chemosensitivity and radiosensitivity Oncogene 2003, 22(47):7486-7495 14576853
51. Ferreira CG Tolis C Giaccone G p53 and chemosensitivity Ann Oncol 1999, 10(9):1011-1021 10572598
52. Debernardis D Sire EG De Feudis P Vikhanskaya F Valenti M Russo P Parodi S D'Incalci M Broggini M p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel Cancer Res 1997, 57(5):870-874 9041188
53. Kigawa J Sato S Shimada M Takahashi M Itamochi H Kanamori Y Terakawa N p53 gene status and chemosensitivity in ovarian cancer Hum Cell 2001, 14(3):165-171 11774736
54. Strano S Blandino G p73-mediated chemosensitivity: A preferential target of oncogenic mutant p53 Cell Cycle 2003, 2(4):348-349 12851488
55. Sax JK El-Deiry WS p53 downstream targets and chemosensitivity Cell Death Differ 2003, 10(4):413-417 12719718
56. Berglind H Pawitan Y Kato S Ishioka C Soussi T Analysis of p53 mutation status in human cancer cell lines: A paradigm for cell line cross-contamination Cancer Biol Ther 2008, 7(5):699-708 18277095
57. Hamroun D Kato S Ishioka C Claustres M Beroud C Soussi T The UMD TP53 database and website: Update and revisions Hum Mutat 2006, 27(1):14-20 16278824
58. Mabuchi S Ohmichi M Nishio Y Hayasaka T Kimura A Ohta T Saito M Kawagoe J Takahashi K Yada-Hashimoto N et al.: Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models J Biol Chem 2004, 279(22):23477-23485 15026414
59. Hayakawa J Ohmichi M Kurachi H Kanda Y Hisamoto K Nishio Y Adachi K Tasaka K Kanzaki T Murata Y Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin Cancer Res 2000, 60(21):5988-5994 11085518
60. Mabuchi S Altomare DA Cheung M Zhang L Poulikakos PI Hensley HH Schilder RJ Ozols RF Testa JR RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res 2007, 13(14):4261-4270 17634556
61. Taylor SA Marrinan CH Liu G Nale L Bishop WR Kirschmeier P Liu M Long BJ Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo Gynecol Oncol 2008, 109(1):97-106 18237771
62. Huang Y Fan W IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines Mol Pharmacol 2002, 61(1):105-113 11752211
63. Bruynzeel AM Abou El Hassan MA Torun E Bast A Vijgh van der WJ Kruyt FA Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells Br J Cancer 2007, 96(3):450-456 17285121
64. Vikhanskaya F Clerico L Valenti M Stanzione MS Broggini M Parodi S Russo P Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53 Int J Cancer 1997, 72(1):155-159 9212237
65. Zeng S Chen YZ Fu L Johnson KR Fan W In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells Clin Cancer Res 2000, 6(9):3766-3773 10999771